IPM Take
Sanfilippo syndrome type B is the kind of disease that exposes the limits of slow systems. A child can lose development, speech, behaviour, movement and eventually life while the regulatory pathway tries to decide what kind of evidence is possible in an ultra-rare neurodegenerative disorder.
Spruce’s pre-BLA update for tralesinidase alfa is therefore not a routine filing story. It is a story about building approval infrastructure around a biomarker-based accelerated-approval pathway, commercial-scale manufacturing and a confirmatory-study plan before an approved therapy exists. The promise is meaningful, but the line must stay clear: alignment on the path is not proof that the treatment changes the disease.
Executive Summary
Spruce Biosciences announced that it completed two pre-BLA meetings with FDA supporting its planned fourth-quarter 2026 Biologics License Application for tralesinidase alfa enzyme replacement therapy, or TA-ERT, for Sanfilippo syndrome type B, also known as MPS IIIB.
According to Spruce, FDA found the company’s chemistry, manufacturing and controls comparability strategies reasonable following transfer to a commercial-scale manufacturer. Spruce also said FDA aligned on the overall content and format of the planned BLA and that the company continues to pursue accelerated approval based on reduction of cerebrospinal-fluid heparan sulfate non-reducing ends.
TA-ERT has been evaluated in three clinical studies and administered to 22 individuals with MPS IIIB, according to the company. The planned BLA is not yet submitted, the therapy is not approved, and the clinical benefit still requires regulatory review and confirmatory evidence.
Why it matters
- Patients / advocates: Families facing MPS IIIB have no FDA-approved disease-modifying therapy and need regulatory urgency matched with honest communication about uncertainty.
- Regulators: The case tests how biomarker-based accelerated approval can be applied in an ultra-rare paediatric neurodegenerative disease.
- Clinicians: If the programme advances, referral, diagnosis, eligibility and intracerebroventricular delivery capacity will become practical barriers.
- Industry / innovation partners: Manufacturing comparability and commercial readiness are not back-office details; in ultra-rare disease, they determine whether approval can become availability.
Sanfilippo syndrome type B is not only rare. It is relentlessly unfair. Children may develop symptoms after an early period that appears less alarming, then face progressive neurodegeneration that affects cognition, behaviour, speech, movement and care needs. Families often become experts in a disease most systems barely recognise.
Spruce’s update matters because it suggests the regulatory machinery is moving closer to a submission. The company says FDA alignment now covers the planned BLA structure, the accelerated-approval biomarker strategy and the manufacturing comparability approach after technology transfer. Those details may sound administrative, but in an ultra-rare disease they can decide whether an application is reviewable and whether a product can be manufactured at commercial scale.
The evidence question remains difficult. Accelerated approval based on a cerebrospinal-fluid biomarker may be scientifically and ethically reasonable in a disease where waiting for conventional clinical endpoints can be devastating. But a biomarker must still be tied to a credible expectation of clinical benefit, and families must not be asked to confuse regulatory progress with established treatment effect.
The next stage should be watched closely because it will test more than one company’s programme. It will test whether the system can move with urgency in paediatric neurodegeneration while remaining honest about what is known, what is inferred and what still needs confirmation.
For IPM, this is the core issue: no child should wait because the pathway is underbuilt, but no family should be given certainty that the evidence has not yet earned.
